Indian"Secret" HIV Virus Trials Probed

6 October 1996

India's Mumbai High Court has ordered an inquiry into alleged secret medical trials conducted on 10 HIV patients at the Indian Health Organization's premises in 1994, using a US-made bovine immunodeficiency virus.

The court has called on the state Food and Drugs Administration and the Maharashtra state government to undertake the inquiry into the experiment, in which the BIV vaccine was allegedly given without testing and without the permission of the national drug controller. The case arose out of a writ filed by one of the patients, claiming that they were treated "worse than guinea pigs" and had been misinformed about the vaccine. The World Health Organization had assessed the trials as unscientific and unethical.

The court said that if the inquiry found that IHO president I S Gilada had procured the vaccine without government sanction, action should be taken against him. It also directed Dr Gilada to administer the third dose of the vaccine to the plaintiff who, with other patients, had expressed fears over abandonment of the trials after administration of two doses, on the grounds that the live virus might mutate within their bodies into a deadlier form of HIV. Dr Gilada claims that the trials were without his consent, and said he could not vouch for the drug's efficacy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight